Cargando…

FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

BACKGROUND: The present study aimed to assess the correlation of fibroblast growth factor (FGF)-23 expression with clinical characteristics, then further explore its value in predicting 2-year in-stent restenosis (ISR) risk in coronary heart disease (CHD) patients underwent percutaneous coronary int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Tingting, Fu, Yang, Wang, Yanbo, Li, Wei, Zhao, Jiayu, Wang, Xun, Wang, Haiyan, Zhao, Ying, Fu, Xianghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791850/ https://www.ncbi.nlm.nih.gov/pubmed/33413149 http://dx.doi.org/10.1186/s12872-020-01839-w

Ejemplares similares

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
por: Dinesch, Violeta, et al.
Publicado: (2017)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
por: Xiu, Wen-Juan, et al.
Publicado: (2018)

Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
por: Kim, Ki-Hun, et al.
Publicado: (2009)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Publicado: (2017)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis
por: Song, Jian-bo, et al.
Publicado: (2020)

In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation
por: Kato, Yuta, et al.
Publicado: (2017)

Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation
por: PARK, CHANG-BUM, et al.
Publicado: (2013)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation
por: Luo, Yinhua, et al.
Publicado: (2022)

Intravascular Ultrasound-Guided Treatment for In-stent Restenosis Associated with Stent Fracture in Overlapped Drug-eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2019)

Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis
por: Abdelmegid, Mohamed Aboel-Kassem F., et al.
Publicado: (2017)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis
por: Wang, Jing, et al.
Publicado: (2021)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
por: Ryu, JiWung, et al.
Publicado: (2021)

Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies
por: Gao, Lei, et al.
Publicado: (2019)

Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis
por: Zhao, Lin, et al.
Publicado: (2017)

Impact of Exercise-based Cardiac Rehabilitation on In-stent Restenosis with Different Generations of Drug Eluting Stent
por: Kim, Chul, et al.
Publicado: (2012)

Local drug-delivery balloon for proliferative occlusive in-stent restenosis after drug-eluting stent
por: Rigatelli, Gianluca, et al.
Publicado: (2011)

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents
por: Yin, Jiasheng, et al.
Publicado: (2017)

In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario
por: Paramasivam, Ganesh, et al.
Publicado: (2019)

State-of-the-Art Stent Technology to Minimize the Risk of Stent Thrombosis and In-Stent Restenosis: Abluminal-Coated Biodegradable Polymer Drug-Eluting Stent
por: Kang, Dong Oh, et al.
Publicado: (2022)

Multiple Sequential Complications After Sirolimus-Eluting Stent Implantation: Very Late Stent Thrombosis, Stent Fracture, In-Stent Restenosis, and Peri-Stent Aneurysm
por: Seol, Sang-Hoon, et al.
Publicado: (2009)

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis
por: Yin, Rui-Xing, et al.
Publicado: (2014)

Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation
por: Liang, Hengyi, et al.
Publicado: (2020)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes
por: Paramasivam, Ganesh, et al.
Publicado: (2020)

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis
por: Cui, Kong-Yong, et al.
Publicado: (2018)

Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents
por: Kim, Yong Hoon, et al.
Publicado: (2019)

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis
por: Yang, Yi-Xing, et al.
Publicado: (2020)

The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation
por: Zhao, Jinbo, et al.
Publicado: (2023)

Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rate
por: Dietz, Ulrich, et al.
Publicado: (2005)

In-Stent Restenosis Exacerbated by Drug-Induced Severe Eosinophilia after Second-Generation Drug-Eluting Stent Implantation
por: Yagi, Hiroki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2ne7sunrgpr4rodsmvmkctbni3